DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Canakinumab is an investigational drug.
There have been 68 clinical trials for Canakinumab. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2014.
The most common disease conditions in clinical trials are Arthritis, Syndrome, and Arthritis, Juvenile. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and Charite University, Berlin, Germany.
There are twenty-two US patents protecting this investigational drug and three hundred and fifty-eight international patents.
Recent Clinical Trials for Canakinumab
|This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.||Novartis Pharmaceuticals||Phase 2|
|A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma||Novartis||Early Phase 1|
|A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma||Charles G. Drake||Early Phase 1|
Top disease conditions for Canakinumab
Top clinical trial sponsors for Canakinumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Canakinumab||Start Trial||Use of IL-1 .beta. binding antibodies for treating peripheral arterial disease||Novartis AG (Basel, CH)||Start Trial|
|Canakinumab||Start Trial||Trilayer coated pharmaceutical packaging||SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)||Start Trial|
|Canakinumab||Start Trial||Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody||The Children's Hospital of Philadelphia (Philadelphia, PA) The Trustees of the University of Pennsylvania (Philadelphia, PA)||Start Trial|
|Canakinumab||Start Trial||Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development||TRUSTEES OF BOSTON UNIVERSITY (Boston, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Canakinumab||European Patent Office||2919811||2032-11-16||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|